These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35343198)

  • 1. Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety.
    Raja T; Sud R; Addla S; Sarkar KK; Sridhar PS; Talreja V; Jain M; Patil K
    Indian J Cancer; 2022 Mar; 59(Supplement):S142-S159. PubMed ID: 35343198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
    Bolton EM; Lynch T
    BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
    Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
    Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
    Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.
    Cicione A; Nacchia A; Guercio A; Gravina C; Franco A; Grimaldi MC; Tema G; Lombardo R; Tubaro A; De Nunzio C
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):765-771. PubMed ID: 36641533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.
    Gommersall LM; Hayne D; Shergill IS; Arya M; Wallace DM
    Expert Opin Pharmacother; 2002 Dec; 3(12):1685-92. PubMed ID: 12472366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of GnRH antagonists for prostate cancer: new approaches to treatment.
    Cook T; Sheridan WP
    Oncologist; 2000; 5(2):162-8. PubMed ID: 10794807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical study on the effectiveness and safety of combined laparoscopy and gonadotropin-releasing hormone agonist in the treatment of endometriosis].
    Song JH; Lu H; Zhang J; Li B
    Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):584-8. PubMed ID: 24199923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
    George DJ; Dearnaley DP
    Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens.
    Cho E; Mostaghel EA; Russell KJ; Liao JJ; Konodi MA; Kurland BF; Marck BT; Matsumoto AM; Dalkin BL; Montgomery RB
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):236-43. PubMed ID: 25772183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy.
    Gulley JL; Figg WD; Steinberg SM; Carter J; Sartor O; Higano CS; Petrylak DP; Chatta G; Hussain MH; Dahut WL
    J Urol; 2005 May; 173(5):1567-71. PubMed ID: 15821487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
    Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.